Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 473494 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2018
At a glance
- Drugs BI 473494 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 20 Nov 2018 Status changed from suspended to discontinued due to business reasons.
- 10 Aug 2018 Planned End Date changed from 25 Jun 2018 to 30 Jul 2019.
- 10 Aug 2018 Planned primary completion date changed from 25 Jun 2018 to 30 Jul 2019.